IIRC Dr T said something like this for the EMD AML preclinical:
This preclinical data might be the difference between approval or not if the clinical data is borderline.
It is not required to begin any of the AML trials.
Ann: Compelling Zantrene Preclinical Kidney Cancer Data, page-56
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.095(5.44%) |
Mkt cap ! $281.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.62 | $285.9K | 170.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16759 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 12047 | 1 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |